276 related articles for article (PubMed ID: 16826310)
1. Meningococcal conjugate vaccines: efficacy and new combinations.
Sáfadi MA; Barros AP
J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S35-44. PubMed ID: 16826310
[TBL] [Abstract][Full Text] [Related]
2. A critical appraisal of the recommendations for the use of meningococcal conjugate vaccines.
Sáfadi MA; Berezin EN; Oselka GW
J Pediatr (Rio J); 2012 May; 88(3):195-202. PubMed ID: 22622596
[TBL] [Abstract][Full Text] [Related]
3. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
Noronha CP; Struchiner CJ; Halloran ME
Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
[TBL] [Abstract][Full Text] [Related]
5. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
[TBL] [Abstract][Full Text] [Related]
6. Vaccines for the prevention of meningococcal disease in children.
Soriano-Gabarró M; Stuart JM; Rosenstein NE
Semin Pediatr Infect Dis; 2002 Jul; 13(3):182-9. PubMed ID: 12199614
[TBL] [Abstract][Full Text] [Related]
7. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.
Borrow R; Alarcón P; Carlos J; Caugant DA; Christensen H; Debbag R; De Wals P; Echániz-Aviles G; Findlow J; Head C; Holt D; Kamiya H; Saha SK; Sidorenko S; Taha MK; Trotter C; Vázquez Moreno JA; von Gottberg A; Sáfadi MA;
Expert Rev Vaccines; 2017 Apr; 16(4):313-328. PubMed ID: 27820969
[TBL] [Abstract][Full Text] [Related]
8. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
[TBL] [Abstract][Full Text] [Related]
9. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
[TBL] [Abstract][Full Text] [Related]
11. Meningococcal conjugate vaccines.
Zimmer SM; Stephens DS
Expert Opin Pharmacother; 2004 Apr; 5(4):855-63. PubMed ID: 15102568
[TBL] [Abstract][Full Text] [Related]
12. Meningococcal vaccine evolution.
Bona G; Guidi C
J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
[TBL] [Abstract][Full Text] [Related]
13. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil.
Andrade AL; Minamisava R; Tomich LM; Lemos AP; Gorla MC; de Cunto Brandileone MC; Domingues CMS; de Moraes C; Policena G; Bierrenbach AL;
Vaccine; 2017 Apr; 35(16):2025-2033. PubMed ID: 28318769
[TBL] [Abstract][Full Text] [Related]
14. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
[TBL] [Abstract][Full Text] [Related]
15. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.
Borrow R; Miller E
Expert Rev Vaccines; 2006 Dec; 5(6):851-7. PubMed ID: 17184222
[TBL] [Abstract][Full Text] [Related]
16. Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.
Dretler AW; Rouphael NG; Stephens DS
Hum Vaccin Immunother; 2018 May; 14(5):1146-1160. PubMed ID: 29543582
[TBL] [Abstract][Full Text] [Related]
17. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
[TBL] [Abstract][Full Text] [Related]
18. The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines.
Pelton SI
J Adolesc Health; 2016 Aug; 59(2 Suppl):S3-S11. PubMed ID: 27449148
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal disease: risk for international travellers and vaccine strategies.
Wilder-Smith A
Travel Med Infect Dis; 2008 Jul; 6(4):182-6. PubMed ID: 18571105
[TBL] [Abstract][Full Text] [Related]
20. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile.
Villena R; Valenzuela MT; Bastías M; Santolaya ME
Vaccine; 2019 Oct; 37(46):6915-6921. PubMed ID: 31585728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
